Takeda Pharmaceutical (TAK) reported fiscal Q3 core earnings Thursday of 132 Japanese yen ($0.84) per basic share, down from 150 yen a year earlier.

Four analysts polled by FactSet expected 124 yen.

Revenue for the quarter ended Dec. 31 was 1.144 trillion yen, up from 1.111 trillion yen a year earlier.

Analysts surveyed by FactSet expected 1.138 trillion yen.

The company now expects core earnings guidance for the fiscal year ended March 31 to be 507 yen per share, compared with its prior guidance of 456 yen set on Oct. 31, 2024.

Analysts surveyed by FactSet expect 480 yen.

The company now expects revenue for the fiscal year of 4.59 trillion yen, compared with its prior guidance of 4.48 trillion yen. A single analyst polled by FactSet expects 4.562 trillion yen.

Shares of the company rose 3.5% in premarket activity Thursday.